1-12 of 12
Maximilian von Eynatten
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes

Petter Bjornstad, Lori Laffel, William V. Tamborlane, Gudrun Simons, Stefan Hantel, Maximilian von Eynatten, Jyothis George, Jan Marquard, David Z.I. Cherney
Journal: Diabetes Care
Diabetes Care 2018;41(8):e129–e130
https://doi.org/10.2337/dc18-0394
Published: 25 June 2018
View article titled, Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes
Open the PDF for Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes in another window
Journal Articles

Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?

Nikolaus Marx, Darren K. McGuire, Vlado Perkovic, Hans-Juergen Woerle, Uli C. Broedl, Maximilian von Eynatten, Jyothis T. George, Julio Rosenstock
Journal: Diabetes Care
Diabetes Care 2017;40(9):1144–1151
https://doi.org/10.2337/dc17-0068
Published: 14 August 2017
View article titled, Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
Open the PDF for Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point? in another window
Journal Articles

Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial

Markku Laakso, Julio Rosenstock, Per-Henrik Groop, Anthony H. Barnett, Baptist Gallwitz, Uwe Hehnke, Ilkka Tamminen, Sanjay Patel, Maximilian von Eynatten, Hans-Juergen Woerle
Journal: Diabetes Care
Diabetes Care 2015;38(2):e15–e17
https://doi.org/10.2337/dc14-1684
Published: 10 January 2015
View article titled, Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial
Open the PDF for Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial in another window
Journal Articles

Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction

Per-Henrik Groop, MD, Mark E. Cooper, MBBS, Vlado Perkovic, MBBS, Angela Emser, PHD, Hans-Juergen Woerle, MD, Maximilian von Eynatten, MD
Journal: Diabetes Care
Diabetes Care 2013;36(11):3460–3468
https://doi.org/10.2337/dc13-0323
Published: 15 October 2013
View article titled, Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
Open the PDF for Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction in another window
Includes: Supplementary data
Journal Articles

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study

Janet B. McGill, MD, Lance Sloan, MD, Jennifer Newman, BS, Sanjay Patel, MB, Christophe Sauce, MS, Maximilian von Eynatten, MD, Hans-Juergen Woerle, MD
Journal: Diabetes Care
Diabetes Care 2013;36(2):237–244
https://doi.org/10.2337/dc12-0706
Published: 17 January 2013
View article titled, Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: <subtitle>A 1-year, randomized, double-blind, placebo-controlled study</subtitle>
Open the PDF for Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: <subtitle>A 1-year, randomized, double-blind, placebo-controlled study</subtitle> in another window
Includes: Supplementary data
Journal Articles

PPARγ Variant Influences Angiographic Outcome and 10-Year Cardiovascular Risk in Male Symptomatic Coronary Artery Disease Patients: Response to Regieli et al.

Jochen G. Schneider, MD, Stephan Schiekofer, MD, Maximilian von Eynatten, MD, Klaus A. Dugi, MD
Journal: Diabetes Care
Diabetes Care 2009;32(6):e75
https://doi.org/10.2337/dc09-0393
Published: 01 June 2009
View article titled, <em>PPAR</em>γ Variant Influences Angiographic Outcome and 10-Year Cardiovascular Risk in Male Symptomatic Coronary Artery Disease Patients: <subtitle>Response to Regieli et al.</subtitle>
Open the PDF for <em>PPAR</em>γ Variant Influences Angiographic Outcome and 10-Year Cardiovascular Risk in Male Symptomatic Coronary Artery Disease Patients: <subtitle>Response to Regieli et al.</subtitle> in another window
Journal Articles

Total and High–Molecular Weight Adiponectin in Relation to Metabolic Variables at Baseline and in Response to an Exercise Treatment Program: Comparative Evaluation of Three Assays: Response to Blüher et al.

Maximilian von Eynatten, MD, Philipp M. Lepper, MD, Per M. Humpert, MD
Journal: Diabetes Care
Diabetes Care 2007;30(7):e67
https://doi.org/10.2337/dc07-0398
Published: 01 July 2007
View article titled, Total and High–Molecular Weight Adiponectin in Relation to Metabolic Variables at Baseline and in Response to an Exercise Treatment Program: Comparative Evaluation of Three Assays: <subtitle>Response to Blüher et al.</subtitle>
Open the PDF for Total and High–Molecular Weight Adiponectin in Relation to Metabolic Variables at Baseline and in Response to an Exercise Treatment Program: Comparative Evaluation of Three Assays: <subtitle>Response to Blüher et al.</subtitle> in another window
Journal Articles

Low Plasma Adiponectin Levels Are Associated With Increased Hepatic Lipase Activity In Vivo : Response to Kobayashi et al.

Jochen G. Schneider, MD, Maximilian von Eynatten, MD, Stephan Schiekofer, MD, Peter P. Nawroth, MD, Klaus A. Dugi, MD
Journal: Diabetes Care
Diabetes Care 2006;29(1):181
https://doi.org/10.2337/diacare.29.01.06.dc05-1962
Published: 01 January 2006
View article titled, Low Plasma Adiponectin Levels Are Associated With Increased Hepatic Lipase Activity In Vivo : <subtitle>Response to Kobayashi et al.</subtitle>
Open the PDF for Low Plasma Adiponectin Levels Are Associated With Increased Hepatic Lipase Activity In Vivo : <subtitle>Response to Kobayashi et al.</subtitle> in another window
Journal Articles

Low Plasma Adiponectin Levels Are Associated With Increased Hepatic Lipase Activity In Vivo

Jochen G. Schneider, MD, Maximilian von Eynatten, MD, Stephan Schiekofer, MD, Peter P. Nawroth, MD, Klaus A. Dugi, MD
Journal: Diabetes Care
Diabetes Care 2005;28(9):2181–2186
https://doi.org/10.2337/diacare.28.9.2181
Published: 01 September 2005
View article titled, Low Plasma Adiponectin Levels Are Associated With Increased Hepatic Lipase Activity In Vivo
Open the PDF for Low Plasma Adiponectin Levels Are Associated With Increased Hepatic Lipase Activity In Vivo in another window
Journal Articles

SDF-1 Genotype Influences Insulin-Dependent Mobilization of Adult Progenitor Cells in Type 2 Diabetes

Per M. Humpert, MD, Renate Neuwirth, Marco J. Battista, Olga Voronko, MD, Maximilian von Eynatten, MD, Ilze Konrade, MD, Gottfried Rudofsky, Jr, MD, Thoralf Wendt, MD, Andreas Hamann, MD, Michael Morcos, MD, Peter P. Nawroth, MD, Angelika Bierhaus, PHD
Journal: Diabetes Care
Diabetes Care 2005;28(4):934–936
https://doi.org/10.2337/diacare.28.4.934
Published: 01 April 2005
View article titled, SDF-1 Genotype Influences Insulin-Dependent Mobilization of Adult Progenitor Cells in Type 2 Diabetes
Open the PDF for SDF-1 Genotype Influences Insulin-Dependent Mobilization of Adult Progenitor Cells in Type 2 Diabetes in another window
Journal Articles

Adipocytokines as a Novel Target for the Anti-inflammatory Effect of Atorvastatin in Patients With Type 2 Diabetes

Maximilian von Eynatten, MD, Jochen G. Schneider, MD, Senad Hadziselimovic, MD, Andreas Hamann, MD, Angelika Bierhaus, PHD, Peter P. Nawroth, MD, Klaus A. Dugi, MD
Journal: Diabetes Care
Diabetes Care 2005;28(3):754–755
https://doi.org/10.2337/diacare.28.3.754
Published: 01 March 2005
View article titled, Adipocytokines as a Novel Target for the Anti-inflammatory Effect of Atorvastatin in Patients With Type 2 Diabetes
Open the PDF for Adipocytokines as a Novel Target for the Anti-inflammatory Effect of Atorvastatin in Patients With Type 2 Diabetes in another window
Journal Articles

Decreased Plasma Lipoprotein Lipase in Hypoadiponectinemia: An association independent of systemic inflammation and insulin resistance

Maximilian von Eynatten, MD, Jochen G. Schneider, MD, Per M. Humpert, MD, Gottfried Rudofsky, MD, Nikolaus Schmidt, MD, Patrizia Barosch, MD, Andreas Hamann, MD, Michael Morcos, MD, Joerg Kreuzer, MD, Angelika Bierhaus, PHD, Peter P. Nawroth, MD, Klaus A. Dugi, MD
Journal: Diabetes Care
Diabetes Care 2004;27(12):2925–2929
https://doi.org/10.2337/diacare.27.12.2925
Published: 01 December 2004
View article titled, Decreased Plasma Lipoprotein Lipase in Hypoadiponectinemia: <subtitle>An association independent of systemic inflammation and insulin resistance </subtitle>
Open the PDF for Decreased Plasma Lipoprotein Lipase in Hypoadiponectinemia: <subtitle>An association independent of systemic inflammation and insulin resistance </subtitle> in another window